Literature DB >> 21112783

Chalcone-based inhibitors against hypoxia-inducible factor 1--structure activity relationship studies.

Balasubramanian Srinivasan1, Thomas E Johnson, Chengguo Xing.   

Abstract

Many tumor tissues are under hypoxic conditions. Activating hypoxia-inducible factor 1 (HIF-1), a transcription factor, is a major mechanism for tumor cells to survive and even to evade other tissues. Therefore inhibiting HIF-1 is a potential strategy to help improve cancer treatment. Chalcone is a promising template to develop HIF-1 inhibitor because quite a few of chalcone-based compounds reveal moderate HIF-1 inhibitory activity and many chalcone-based compounds demonstrate promising anticancer activities in various animal models. However, there are no reports about the structure-activity relationship of chalcone compounds with respect to HIF-1 inhibition. This study reports the HIF-1 inhibitory activities of a panel of chalcones, identifies a few lead candidates of single-digit micromolar potency, and determines important structural modifications. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112783      PMCID: PMC3010284          DOI: 10.1016/j.bmcl.2010.10.063

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  18 in total

1.  Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1.

Authors:  Moon-Kyoung Bae; Se-Hee Kim; Joo-Won Jeong; You Mie Lee; Hae-Sun Kim; Su-Ryun Kim; Il Yun; Soo-Kyung Bae; Kyu-Won Kim
Journal:  Oncol Rep       Date:  2006-06       Impact factor: 3.906

2.  Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition.

Authors:  Hyunsung Choi; Yang-Sook Chun; Seung-Won Kim; Myung-Suk Kim; Jong-Wan Park
Journal:  Mol Pharmacol       Date:  2006-07-31       Impact factor: 4.436

3.  Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice.

Authors:  Xiaolin Zi; Anne R Simoneau
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

Review 4.  NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach.

Authors:  Laurence J Egan; Murat Toruner
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

5.  Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma.

Authors:  Shoji Yamazaki; Tatuo Morita; Hitoshi Endo; Toshiro Hamamoto; Masaki Baba; Yoshiko Joichi; Sanae Kaneko; Yoshihito Okada; Toru Okuyama; Hoyoku Nishino; Akihiko Tokue
Journal:  Cancer Lett       Date:  2002-09-08       Impact factor: 8.679

6.  Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis.

Authors:  Masaki Baba; Ryoya Asano; Ikumi Takigami; Tetsuyuki Takahashi; Masayoshi Ohmura; Yoshihito Okada; Hajime Sugimoto; Tadashi Arika; Hoyoku Nishino; Toru Okuyama
Journal:  Biol Pharm Bull       Date:  2002-02       Impact factor: 2.233

7.  Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development.

Authors:  Tetsuyuki Takahashi; Nobuo Takasuka; Masaaki Iigo; Masaki Baba; Hoyoku Nishino; Hiroyuki Tsuda; Toru Okuyama
Journal:  Cancer Sci       Date:  2004-05       Impact factor: 6.716

Review 8.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

Review 9.  Evaluation of HIF-1 inhibitors as anticancer agents.

Authors:  Gregg L Semenza
Journal:  Drug Discov Today       Date:  2007-09-18       Impact factor: 7.851

10.  Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse.

Authors:  S Sale; R G Tunstall; K C Ruparelia; P C Butler; G A Potter; W P Steward; A J Gescher
Journal:  Invest New Drugs       Date:  2006-11       Impact factor: 3.850

View more
  2 in total

1.  Novel 3-(3, 5-difluoro-4-hydroxyphenyl)-1-(naphthalen-2-yl) prop-2-en-1-one as a potent inhibitor of MAP-kinase in HeLa cell lines and anti-angiogenic activity is mediated by HIF-1α in EAC animal model.

Authors:  Dileep Kumar M Guruswamy; Kyathegowdana Doddi Srivinavasa Balaji; Kattepura Krishnappa Dharmappa; Shankar Jayarama
Journal:  Oncotarget       Date:  2020-12-15

2.  An update on antitumor activity of naturally occurring chalcones.

Authors:  En-Hui Zhang; Ru-Feng Wang; Shu-Zhen Guo; Bin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-17       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.